Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-07-25
2006-07-25
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388800, C530S391700, C424S133100, C424S135100, C424S155100, C424S181100, C435S069600, C536S023530
Reexamination Certificate
active
07081518
ABSTRACT:
Mesothelin is a differentiation antigen present on the surface of ovarian cancers, mesotheliomas and several other types of human cancers. Because among normal tissues, mesothelin is only present on mesothelial cells, it represents a good target for antibody mediated delivery of cytotoxic agents. The present invention is directed to anti-mesothelin antibodies, including Fv molecules with particularly high affinity for mesothelin, and immunoconjugates employing them. Also described are diagnostic and therapeutic methods using the antibodies. The anti-mesothelin antibodies are well-suited for the diagnosis and treatment of cancers of the ovary, stomach, squamous cells, mesotheliomas and other malignant cells expressing mesothelin.
REFERENCES:
patent: 5320956 (1994-06-01), Willingham et al.
patent: 5498698 (1996-03-01), Yamaguchi et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5723318 (1998-03-01), Yamaguchi et al.
patent: 5747654 (1998-05-01), Pastan et al.
patent: 5977322 (1999-11-01), Marks et al.
patent: 6083502 (2000-07-01), Pastan et al.
patent: 6153430 (2000-11-01), Pastan et al.
patent: 6809184 (2004-10-01), Pastan et al.
patent: WO 92/07081 (1992-04-01), None
patent: WO 97/25068 (1997-07-01), None
patent: WO 97/34634 (1997-09-01), None
Rudikoff et al. Proc. Natl. Acad. Sci. USA 1982 vol. 79, pp. 1979-1983.
William E. Paul M.D. ed. Fundamenta immunology. 3rd ed. 1993, p. 242.
Yelton et al. The Journal of Immunology. 155: 1994-2004, 1995.
Goyenechea et al. Proc. Natl. Acad. Sci. USA. 93:13979-13984,1996.
Wagner et al. Nature 376: 732, Aug. 31, 1995.
Chowdhury et al. Proc. Natl. Acad. Sci. USA 95: 669-674, Jan. 1998.
Dhowdhury et al. Journal of Molecular Biology. 281: 917-928, 1998.
Schier et al. Journal of Molecular Biology, 263:551-567, 1996.
Brinkman, U. et al., “Cloning and Expression of the Roconbinant FAb Fragment of Monoclonal Antibody K1 that Reacts with Mesothelin Present on Mesotheliomas and Ovarian Cancers,”International Journal of Cancer, May 16, 1997, vol. 71, No. 4, pp. 638-644.
Chang, K., et al., “Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers,”Proc. Natl. Acad. Sci. USA, Jan. 1996, vol. 93, pp. 136-140.
Chang, K., et al., “Characterization of the Antigen (CAK1) Recognized by Monoclonal Antibody K1 Present on Ovarian Cancers and Normal Mesothelium,”Cancer Research, Jan. 1, 1992, vol. 52, No. 1, pp. 181-186.
Chowdhury, P., et al., “Isolation of Anti-Mesothelin Antibodies From A Phage Display Library,”Molecular Immunology, Jan. 1997, vol. 34, No. 1, pp. 9-20.
Chowdhury, P., et al., “Improving antibody affinity by mimicking somatic hypermutation In vitro,”Nature Biotechnology, Jun. 1999, vol. 17, pp. 568-572.
Colman, P.M., “Effects of amino acid sequence changes on antibody-antigen interactions,”Research in Immunology, 1994, vol. 145, pp. 33-36.
Davies, J. et al., “Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding,”Immunotechnology, 1996, vol. 2, No. 3, pp. 169-179.
Dorner, T., et al., “Delineation of Selective Influences Shaping the Mutated Expressed Human Ig Heavy Chain Repertoire, ”J. Immunol., 1998, vol. 160, No. 6, pp. 2831-2841.
Green, N., et al., “Somatic hypermutation of antibody genes: a hot spot warms up,”BioEssaays, Mar. 1998, vol. 20, No. 3, pp. 227-234.
Heidelberg, Database EMBL (EMPRO) EMBL, Mar. 10, 1998.
Kuby, J., W.H., “Chapter 6: Antigen-Antibody Interactions,”Immunology, Second Edition, Freeman and Company, New York, USA, 1994, pp. 136-134.
Wu, G., et al., “Stepwise in vitro affinity maturation of Vitaxin, an αvβ3-specific humanized mAb,”Proc. Natl. Acad. Sci. US, May 1998, vol. 95, pp. 6037-6042.
Yamaguchi, N., et al., “A Novel Cytokine Exhibiting Megakaryocyte Potentiating Activity form a Human Pancreatic Tumor Cell Line HPC-Y5,”The Journal of Biological Chemistry, 1994, pp. 805-808.
Chowdhury Partha S.
Pastan Ira
Blanchard David J.
Helms Larry R.
The United States of America as represented by the Department of
Townsend and Townsend / and Crew LLP
LandOfFree
Anti-mesothelin antibodies having high binding affinity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-mesothelin antibodies having high binding affinity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-mesothelin antibodies having high binding affinity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3550119